The success of targeting BCL-2 family members clinically, particularly with the FDA approval of venetoclax, has demonstrated the clinical potential of this class of agents and transformed the approaches to targeting hematological cancers. The gene discussed is BCL2; the disease is hematopoietic and lymphoid cell neoplasm.